NCT07000851

Imaging Studies in Corticobasal Syndrome

Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 80 (estimated)
• Sponsor: Jennifer Whitwell · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.

Detailed description

Corticobasal syndrome (CBS) is a neurodegenerative disorder characterized by cognitive and behavioral change, as well as asymmetric parkinsonism, dystonia, myoclonus, and limb apraxia. Emerging evidence suggests neuroinflammation plays a key role in the pathogenesis of neurodegenerative disease, including the 4R tauopathies and AD, and neuroinflammation has been linked mechanistically to damage of the white matter. The primary goal of this study is to investigate inflammation and white matter damage using imaging and blood samples. The investigator's will use the PET ligand 11C-ER176 to assess patterns of neuroinflammation in the brain and Neurite Orientation Dispersion and Density Imaging (NODDI) to measure white matter microstructure, including axonal density and alignment. The investigator's will also investigate blood plasma metrics, including neurofilament light chain and plasma glial fibrillary acidic protein (GFAP) that measure neuroaxonal injury and astrogliosis, and inflammation and tau metrics. The investigator's will employ beta-amyloid (A) and tau (T) PET to subdivide the CBS patients into those with biomarker AD (A+T+, CBS-AD) and those without biomarker AD (CBS-4R). The investigator's will also compare these groups to disease controls with typical amnestic biomarker AD (Amn-AD) and healthy controls (HC) that have previously been recruited for other grants (existing data collected under approved IRBs).

Conditions

• Cortico Basal Degeneration
• Corticobasal Syndrome
• Corticobasal Syndrome(CBS)
• Corticobasal Degeneration
• Corticobasal Degeneration (CBD)
• Corticobasal Syndrome (CBS)

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	C-11 ER176 Radiotracer	PET scan looking for inflammation
DIAGNOSTIC_TEST	C-11 PiB	PET scan looking for amyloid protein
DIAGNOSTIC_TEST	AV1451 Tau	Pet scan looking for Tau protein

Timeline

• Start date: 2025-06-25
• Primary completion: 2030-03-30
• Completion: 2031-03-30
• First posted: 2025-06-03
• Last updated: 2025-07-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study